MedTrace Logo

Dose Tolerance Study in Healthy Male Volunteers After Intranasal Application of Epinastine Nasal

NCT02260037 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2014-10-09

No results posted yet for this study

Summary

Safety, tolerability and pharmacokinetics

Conditions

  • Healthy

Interventions

DRUG

Epinastine nasal

DRUG

Placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-08-31
Primary Completion
2001-09-30

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02260037 on ClinicalTrials.gov